Asia Pacific Influenze Vaccine Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Asia Pacific Influenze Vaccine Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Asia Pacific Influenze Vaccine Market to Surpass US$ XX Bn by 2025, Due to Increased Incidence of Seasonal Influenza in the APAC region

“The Asia Pacific Influenza Vaccine Market is anticipated to reach about US$ XX Bn by 2025, and anticipated to expand at a CAGR over seven years of forecast period 2019-2025” owing to an increased incidence of seasonal influenza in the APAC region can be linked to its aging population.

Precision Business Insights (PBI) in its report titled “Asia Pacific Influenza Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The Asia Pacific influenza vaccine market size was accounted for US$ XX Bn in 2018 and anticipated to account for US$ XX Bn by 2025. An increased incidence of seasonal influenza in the APAC region can be linked to its aging population, modernization, changing dietary habits, excessive consumption of preserved food, and high incidence of influenza virus infection. In addition, the market will witness greater competition in the next six to seven years due to increased focus from large pharmaceutical players.

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/asia-pacific-influenza-treatment-market/#ulp-h4n2eZVGqb32xpPc

Asia Pacific influenza vaccine market segmented on the basis of drug class, route of administration, and distribution channel.

Hospitals Expected to Dominate the Revenue Share.

Based on end use the influenza vaccine market is segmented into hospitals, laboratories, and point of care testing laboratories. The hospitals market for influenza diagnostics held the largest market share in 2017. POCTs is expected to be the fastest growing segment owing to the factors such as ease of use and usage by anyone and not requiring much expertise, except basic operational knowledge. With the advent of technologically advanced POCT, the reliance of the public and physicians on these tests has significantly increased. On the other hand, the laboratory influenza diagnostic market is expected to grow at a steady CAGR during the study period.

Asia-Pacific, Accounts for Major Revenue Share for Influenza Vaccine Market

Precision Business Insights (PBI) Asia Pacific influenza vaccine market report analyses the market in different regions of Asia Pacific. According to regional analysis, the Asia Pacific region is expected to witness fast-paced growth during the forecast period. The adoption of new technology and increasing awareness among the people are expected to catapult market growth. One of the major concerning factors about influenza in Asia is the human infection with avian influenza A (H5NI) that resulted in an influenza pandemic. Japan influenza vaccine market is expected to grow at a high CAGR due to rising incidence of influenza among population. China influenza vaccine market is poised to grow during the forecast period due to increasing awareness about vaccination, increase in the healthcare expenditure. India influenza vaccine market is driven by increase in the number of geriatric population and rise in the incidence of disease.

New Product Launch Plays Vital Role in Asia Pacific Influenza Vaccine Market

The increased R&D investment from pharmaceutical companies, research organizations and biotech companies are expected to create demand for influenza vaccine market. For instance, in March 2018, Japanese Pharma Company Shionogi launched single-dose flu drug Xofluza (Baloxsvir marboxil) in Japan
Key player’s profiles in the report are Novartis, MedImmune, Solvay, Hualun Biologicals, Seqirus, MedImmune, GlaxoSmithKline, CSL, Sanofi-Pasteur, Sinovac Biotech, ID Biomedical Corp. of Quebec, and Protein Sciences among others.
Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/asia-pacific-influenza-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Detailed Segmentation

By Drug Class Type

o Anti-viral drugs
o Zanamivir
o Oseltamivir
o Amantadine
o Rimantadine
o Others
o Interferons
o Vaccines
o Trivalent
o Quadrivalent

By Route of Administration Type

o Oral
o Anti-viral drugs
o Parenteral
o Interferon alfa-2b
o Others

By Distribution Channel

o Hospital pharmacies
o Retail pharmacies
o Others

Geography

o Asia-Pacific
 China
 Japan
 India
 ASEAN
 Rest of Asia Pacific

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/asia-pacific-influenza-treatment-market/

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ www.precisionbusinessinsights.com

This release was published on openPR.